1. Home
  2. NRC vs MDWD Comparison

NRC vs MDWD Comparison

Compare NRC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Research Corporation (Delaware)

NRC

National Research Corporation (Delaware)

HOLD

Current Price

$15.85

Market Cap

278.8M

Sector

Health Care

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.56

Market Cap

230.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRC
MDWD
Founded
1981
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
278.8M
230.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NRC
MDWD
Price
$15.85
$18.56
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
90.7K
79.1K
Earning Date
01-26-2026
11-20-2025
Dividend Yield
4.03%
N/A
EPS Growth
N/A
N/A
EPS
0.71
N/A
Revenue
$139,102,000.00
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
N/A
$25.33
P/E Ratio
$22.35
N/A
Revenue Growth
N/A
6.15
52 Week Low
$9.76
$14.14
52 Week High
$19.94
$22.51

Technical Indicators

Market Signals
Indicator
NRC
MDWD
Relative Strength Index (RSI) 49.78 57.04
Support Level $15.90 $17.23
Resistance Level $16.53 $18.18
Average True Range (ATR) 0.73 0.75
MACD -0.24 0.06
Stochastic Oscillator 7.88 94.08

Price Performance

Historical Comparison
NRC
MDWD

About NRC National Research Corporation (Delaware)

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: